Literature DB >> 11056473

A neuro (endo)crine regulation of bone remodeling.

M Amling1, S Takeda, G Karsenty.   

Abstract

Bone remodeling is the normal physiologic process that is used by vertebrates to maintain a constant bone mass during the period bracketed by the end of puberty and the onset of gonadal failure in later life. Besides the well-characterized and critical process of local regulation of bone remodeling, achieved by autocrine and paracrine mechanisms, recent genetic studies have shown that there is a central control of bone formation, mediated by a neuroendocrine mechanism. This central regulation involves leptin, an adipocyte-secreted hormone that controls body weight, reproduction and bone remodeling, and which binds to and exerts its effect through the cells of the hypothalamic nuclei in the brain. This genetic result in mice is in line with clinical observations in humans and generates a whole new direction of research in bone physiology. BioEssays 22:970-975, 2000. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11056473     DOI: 10.1002/1521-1878(200011)22:11<970::AID-BIES3>3.0.CO;2-L

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  17 in total

Review 1.  Evolutionary medicine and bone loss in chronic inflammatory diseases--A theory of inflammation-related osteopenia.

Authors:  Rainer H Straub; Maurizio Cutolo; Roberto Pacifici
Journal:  Semin Arthritis Rheum       Date:  2015-04-30       Impact factor: 5.532

Review 2.  Bone mechanotransduction may require augmentation in order to strengthen the senescent skeleton.

Authors:  Sundar Srinivasan; Ted S Gross; Steven D Bain
Journal:  Ageing Res Rev       Date:  2012-01-05       Impact factor: 10.895

3.  Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females.

Authors:  S Tariq; S Tariq; S S Alam; M Baig
Journal:  Osteoporos Int       Date:  2014-10-02       Impact factor: 4.507

4.  Evaluation of bone microstructure in CRPS-affected upper limbs by HR-pQCT.

Authors:  Haider Mussawy; Tobias Schmidt; Tim Rolvien; Wolfgang Rüther; Michael Amling
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

5.  Mouse models in skeletal physiology and osteoporosis: experiences and data on 14,839 cases from the Hamburg Mouse Archives.

Authors:  Pia Pogoda; Matthias Priemel; Arndt F Schilling; Matthias Gebauer; Philip Catalá-Lehnen; Florian Barvencik; F Timo Beil; Christian Münch; Martin Rupprecht; Cordula Müldner; Johannes M Rueger; Thorsten Schinke; Michael Amling
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

6.  Genetic variation of circulating leptin is involved in genetic variation of hand bone size and geometry.

Authors:  Gregory Livshits; I Pantsulaia; Ia Pantsulaia; Svetlana Trofimov; Eugene Kobyliansky
Journal:  Osteoporos Int       Date:  2003-05-09       Impact factor: 4.507

7.  Reduced size-independent mechanical properties of cortical bone in high-fat diet-induced obesity.

Authors:  S S Ionova-Martin; S H Do; H D Barth; M Szadkowska; A E Porter; J W Ager; J W Ager; T Alliston; C Vaisse; R O Ritchie
Journal:  Bone       Date:  2009-10-21       Impact factor: 4.398

Review 8.  The role of midkine in skeletal remodelling.

Authors:  A Liedert; T Schinke; A Ignatius; M Amling
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

9.  Bone microstructure is significantly altered in CRPS-affected distal tibiae as detected by HR-pQCT: a retrospective cross-sectional study.

Authors:  Nicola Oehler; Tim Rolvien; Tobias Schmidt; Sebastian Butscheidt; Ralf Oheim; Florian Barvencik; Haider Mussawy
Journal:  J Bone Miner Metab       Date:  2018-11-21       Impact factor: 2.626

10.  Lower circulating preptin levels in male patients with osteoporosis are correlated with bone mineral density and bone formation.

Authors:  Ning Li; Yi-Bo Zheng; Jie Han; Wei Liang; Jia-Yi Wang; Jie-Ru Zhou; Yi Shen; Jie Zhang
Journal:  BMC Musculoskelet Disord       Date:  2013-01-31       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.